Charles River Associates names new life sciences VP

By Patricia Resende, Correspondent

Vertex gets European committee nod [May 25, 2012]

EMD Millipore taps John Sweeney to head bio unit [May 25, 2012]

Soteira receives $375K in debt financing [May 25, 2012]

MIT’s needleless injection draws interest from Sanofi [May 25, 2012]

Leading the charge in the life sciences business at Charles River Associates will be David Campbell.

Campbell, who has written a number of publications on the life sciences industry and led a number of emerging market projects, will be a member of the firm’s Life Sciences Practice as vice president of the London office, Charles River Associates said in a news release.

The former principal from IMS Consulting Group, a biotechnology consulting business, was also the managing partner behind Catenion Strategies, a pharmaceutical and medical products consulting company, where he focused his energy on the biotechnology, pharmaceutical and medical diagnostic industries.

Campbell started his career working at hospitals and large companies including in various roles at SmithKline Beechams Pharmaceuticals and as senior investigator at GlaxoSmithKline, both in the United Kingdom.

Campbell’s experience as a management consultant in Europe combined with his work at pharmaceutical companies makes him a strong addition to the company, CRA President and CEO Paul Maleh said in a release.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.